The unpalatability of the KD is due to high fat composition and is one important factor in its unpopularity. This could be partially solved with medium chain triglyceride (MCT) as the major fat source. The MCT-KD therapy was introduced by Liu and Wang. [2] Further modifications such as the Modified Atkin diet and Low glycemic index treatment make dietary therapy easier and more palatable than the classical ones. [3] While the mechanism of action of the KD has not yet been fully eludicated, ketones seem not to be the only contributing factor. The mammalian target of rapamycin pathway may also be related as has been suggested by Wong. [4, 5] The KD could be not only antiepileptic, but also antiepiletogenic. The classic name, ketogenic diet therapy, may more appropriately be replaced by the name metabolic diet therapy.
Beyond epilepsy, there are other promising therapeutic targets for the KD. These include: malignant brain neoplasm, Parkinson disease, Alzheimer's disease, amyotrophic lateral sclerosis, and autism. [1] This special edition includes three review articles on current advances in ketogenic diet therapy for epilepsy management. Authors Dr. Kossoff from the Johns Hopkins Medical Center in Baltimore, Maryland, USA, Dr. Liu from the Hospital for Sick Children in Toronto, Ontario, Canada and Drs Wang and Lin from Chang Gung Children's, Taoyuan, Taiwan are all well recognized experts in the field. The chief editor would like to thank them for their contributions.
